CN100393309C - 具有降低血清葡萄糖和降低血清脂质活性的α-苯硫基羧酸和α-苯氧基羧酸的用途 - Google Patents

具有降低血清葡萄糖和降低血清脂质活性的α-苯硫基羧酸和α-苯氧基羧酸的用途 Download PDF

Info

Publication number
CN100393309C
CN100393309C CNB200380106699XA CN200380106699A CN100393309C CN 100393309 C CN100393309 C CN 100393309C CN B200380106699X A CNB200380106699X A CN B200380106699XA CN 200380106699 A CN200380106699 A CN 200380106699A CN 100393309 C CN100393309 C CN 100393309C
Authority
CN
China
Prior art keywords
thiophenyl
ethyoxyl
methyl
purposes according
isobutyrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200380106699XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1728992A (zh
Inventor
F·基安尼斯
E·塔索尼
M·O·缇恩缇
P·派索托
N·德尔沃莫
A·F·斯阿罗尼
T·布鲁尼缇
F·M·米拉佐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN1728992A publication Critical patent/CN1728992A/zh
Application granted granted Critical
Publication of CN100393309C publication Critical patent/CN100393309C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
CNB200380106699XA 2002-12-19 2003-12-16 具有降低血清葡萄糖和降低血清脂质活性的α-苯硫基羧酸和α-苯氧基羧酸的用途 Expired - Fee Related CN100393309C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2002A000629 2002-12-19
IT000629A ITRM20020629A1 (it) 2002-12-19 2002-12-19 Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante.

Publications (2)

Publication Number Publication Date
CN1728992A CN1728992A (zh) 2006-02-01
CN100393309C true CN100393309C (zh) 2008-06-11

Family

ID=32676886

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200380106699XA Expired - Fee Related CN100393309C (zh) 2002-12-19 2003-12-16 具有降低血清葡萄糖和降低血清脂质活性的α-苯硫基羧酸和α-苯氧基羧酸的用途

Country Status (20)

Country Link
US (1) US7375124B2 (enExample)
EP (1) EP1572180B1 (enExample)
JP (1) JP2006512362A (enExample)
KR (1) KR20050085222A (enExample)
CN (1) CN100393309C (enExample)
AR (1) AR042547A1 (enExample)
AT (1) ATE423558T1 (enExample)
AU (1) AU2003288546B8 (enExample)
BR (1) BR0317359A (enExample)
CA (1) CA2506627A1 (enExample)
DE (1) DE60326382D1 (enExample)
DK (1) DK1572180T3 (enExample)
ES (1) ES2321708T3 (enExample)
IT (1) ITRM20020629A1 (enExample)
MX (1) MXPA05005848A (enExample)
PL (1) PL378414A1 (enExample)
PT (1) PT1572180E (enExample)
SI (1) SI1572180T1 (enExample)
TW (1) TWI308564B (enExample)
WO (1) WO2004056355A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
JP5602728B2 (ja) 2008-06-26 2014-10-08 レスバーロジックス コーポレイション キナゾリノン誘導体の製造方法
KR101395952B1 (ko) * 2008-09-05 2014-05-21 어큐셀라 인코포레이티드 안과 질환 및 장애 치료를 위한 황-연결 화합물
EP2382194B1 (en) 2009-01-08 2014-03-12 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
NZ595747A (en) 2009-03-18 2015-06-26 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
EP2421533B1 (en) 2009-04-22 2018-10-17 Resverlogix Corp. Novel anti-inflammatory agents
LT2773354T (lt) 2011-11-01 2019-08-12 Resverlogix Corp. Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN114901641B (zh) * 2020-02-28 2025-06-17 四川科伦博泰生物医药股份有限公司 芳香族化合物及其药物组合物和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262850A (en) * 1958-06-20 1966-07-26 Ici Ltd Methods for reducing cholesterol in the blood
GB1422679A (en) * 1972-11-16 1976-01-28 Funai Pharmaceutical Ind Ltd Substituted phenoxy-a-methylpropionic acid derivatives and a process for producing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1121722A (en) * 1966-03-31 1968-07-31 Ici Ltd New carboxylic acid derivatives
FR2285859A1 (fr) * 1974-09-30 1976-04-23 Lafon Labor Phenylsulfinyl-amidines et derives
ITRM20020014A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262850A (en) * 1958-06-20 1966-07-26 Ici Ltd Methods for reducing cholesterol in the blood
GB1422679A (en) * 1972-11-16 1976-01-28 Funai Pharmaceutical Ind Ltd Substituted phenoxy-a-methylpropionic acid derivatives and a process for producing the same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Design and Synthesisof2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxylphenoxy}propionicAcids:A New Class of Dual PPARa/r agonists. Dawn A.Brooks.JOURNAL OF MEDICINAL CHEMISTRY,Vol.44 No.13. 2001
Design and Synthesisof2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxylphenoxy}propionicAcids:A New Class of Dual PPARa/r agonists. Dawn A.Brooks.JOURNAL OF MEDICINAL CHEMISTRY,Vol.44 No.13. 2001 *
LR-16 A COMPOUND WITH POTENT EFFECTS ONTHEOXYGEN AFFINITY OF HEMOGLOBIN ONBLOOD CHOLESTEROL AND ON LOW DENSITYLIPOPROTEIN. LALEZARI I.PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES,Vol.85 No.16. 1998
LR-16 A COMPOUND WITH POTENT EFFECTS ONTHEOXYGEN AFFINITY OF HEMOGLOBIN ONBLOOD CHOLESTEROL AND ON LOW DENSITYLIPOPROTEIN. LALEZARI I.PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES,Vol.85 No.16. 1998 *
Role of peroxisome proliferator-activated receptors inatherosclerosis. WINEGAR D A.CURRENT OPINION IN CARDIOVASCULAR,PULMONARY AND RENAL INVESTIGATIONAL DRUGS 2000 UNITED KINGDOM,Vol.2 No.3. 2000
Role of peroxisome proliferator-activated receptors inatherosclerosis. WINEGAR D A.CURRENT OPINION IN CARDIOVASCULAR,PULMONARY AND RENAL INVESTIGATIONAL DRUGS 2000 UNITED KINGDOM,Vol.2 No.3. 2000 *

Also Published As

Publication number Publication date
SI1572180T1 (sl) 2009-06-30
DK1572180T3 (da) 2009-06-02
CN1728992A (zh) 2006-02-01
TW200420531A (en) 2004-10-16
KR20050085222A (ko) 2005-08-29
PL378414A1 (pl) 2006-04-03
MXPA05005848A (es) 2005-08-26
AR042547A1 (es) 2005-06-22
EP1572180B1 (en) 2009-02-25
US7375124B2 (en) 2008-05-20
AU2003288546A1 (en) 2004-07-14
AU2003288546B2 (en) 2009-04-30
CA2506627A1 (en) 2004-07-08
TWI308564B (en) 2009-04-11
BR0317359A (pt) 2005-11-08
US20060154979A1 (en) 2006-07-13
EP1572180A1 (en) 2005-09-14
DE60326382D1 (de) 2009-04-09
ITRM20020629A1 (it) 2004-06-20
JP2006512362A (ja) 2006-04-13
AU2003288546B8 (en) 2009-06-11
HK1087007A1 (en) 2006-10-06
WO2004056355A1 (en) 2004-07-08
ES2321708T3 (es) 2009-06-10
PT1572180E (pt) 2009-05-04
ATE423558T1 (de) 2009-03-15

Similar Documents

Publication Publication Date Title
RU2328483C2 (ru) Индолы, обладающие противодиабетической активностью
DE60128475T2 (de) N-substituierte indole mit anwendung in der behandlung von diabetes
TWI249522B (en) Compounds that modulate PPAR activity and methods for their preparation
CN100393309C (zh) 具有降低血清葡萄糖和降低血清脂质活性的α-苯硫基羧酸和α-苯氧基羧酸的用途
TW200539854A (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
IL145922A (en) History of diarylic acid as PPAR receptor ligands, pharmaceutical preparations containing them and their use in the preparation of drugs
JP2003502369A (ja) アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体
JP2003523336A (ja) 糖尿病及び脂質障害のためのアリールオキシ酢酸
WO2000063189A1 (en) Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
JP2009509932A (ja) Ｐｐａｒ活性化合物
JP2010526807A (ja) 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法
JP2003502370A (ja) アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体
WO2004010992A1 (en) Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
CN100522940C (zh) 用于治疗对PPARα活化有反应的疾病的α-苯硫基羧酸和α-苯氧基-羧酸的衍生物
JP2005514452A (ja) フェニル（アルキル）カルボン酸誘導体およびジオニックフェニルアルキル複素環誘導体およびそれらの血清グルコースおよび／または血清脂質低下活性を有する医薬としての使用
DE60130031T2 (de) Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
WO2000023442A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP4750556B2 (ja) 有効な抗高血糖活性および抗高脂血活性をもつＰＰＡＲｐａｎアゴニストとしての置換アリールアルカン酸誘導体
HK1087007B (en) Use of a-phenylthiocarboxylic and a-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity
CN107434789A (zh) 苯并三氮唑类衍生物、及其制法和药物组合物与用途
CN102786468A (zh) Gk和ppar双重激动活性的烟酸类衍生物
WO2011075935A1 (zh) 二苯基乙烯类衍生物及其用途
TW201102372A (en) Indane analogs and use as pharmaceutical agents and process of making
CN108003074A (zh) 联苯羧酸类化合物及其制备方法和用途
RU2342362C2 (ru) Замещенные производные арилалкановой кислоты как пан агонисты рапп с высокой антигипергликемической и антигиперлипидемической активностью

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1087007

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1087007

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080611

Termination date: 20101216